Skip to content

Safety and efficacy of ganglionated plexus ablation in the hemodialysis patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation

Safety and efficacy of ganglionated plexus ablation in the hemodialysis patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation - Safety and efficacy of ganglionated plexus ablation in the hemodialysis patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018365
Enrollment
200
Registered
2015-07-21
Start date
2015-03-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal atrial fibrillation Renal disease

Interventions

Treatment of ganglionated plexus ablation and pulmonary vein isolation before catheter ablation Treatment of pulmonary vein isolation before catheter ablation

Sponsors

Osaka General Medical Center
Lead Sponsor
Hyogo College of Medicine Osaka Rosai Hospital Kansai Rosai Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. Hemodialysis patients who is planning to receive treatment of first catheter ablation for paroxysmal atrial fibrillation b. Patients who received sufficient explanation, understood it and gave written consent based on their free will, before participating in this study

Exclusion criteria

Exclusion criteria: a. Patients with non-valvular atrial fibrillation, after open heart surgery b. NYHA III or IV c. Peritoneal dialysis patients d. Patients who were judged inappropriate by the principal investigator

Design outcomes

Primary

MeasureTime frame
Recurrence within one year from the first ablation

Secondary

MeasureTime frame
i) Recurrence within one year from the last ablation ii) Procedure time, fluoroscopic time, complications iii) Pulmonary congestion necessary to extend hospital stay iv) Increase in weight after ablation v) Unscheduled hemodialysis vi) Cerebral infarction, systemic thromboembolism vii) All-cause death, cardiac death, sudden death

Countries

Japan

Contacts

Public ContactYoshio Furukawa

Osaka General Medical Center Department of Cardiology

kenkyusien@gh.opho.jp06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026